Intravenous enoxaparin as alternative ECMO anticoagulation over a period of 94 days: a case report
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource, 1 online resource.
- Language
-
Englisch
- Bibliographic citation
-
Intravenous enoxaparin as alternative ECMO anticoagulation over a period of 94 days: a case report ; volume:18 ; number:1 ; day:11 ; month:4 ; year:2023 ; pages:1-4 ; date:12.2023
Journal of cardiothoracic surgery ; 18, Heft 1 (11.4.2023), 1-4, 12.2023
- Creator
-
Durila, Miroslav
Berousek, Jan
Vlasakova, Vlasta
Vymazal, Tomas
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s13019-023-02226-0
- URN
-
urn:nbn:de:101:1-2023082521093465756595
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:45 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Durila, Miroslav
- Berousek, Jan
- Vlasakova, Vlasta
- Vymazal, Tomas
- SpringerLink (Online service)
Other Objects (12)
Anticoagulation in COVID-19: Effect of Enoxaparin, Heparin, and Apixaban on Mortality
Clinical controversies in anticoagulation monitoring and antithrombin supplementation for ECMO
Between a rock and a hard place: anticoagulation management for ECMO
Anticoagulation during ECMO: Will the Tight Rope be Tighter in 2018?
Comparison of anticoagulation strategies for veno-venous ECMO support in acute respiratory failure
Intravenous immunoglobulin fails to improve ARDS in patients undergoing ECMO therapy
Long-term course of ambulatory patients with COVID-19 initially treated with enoxaparin vs no anticoagulation: final analysis of the OVID (enoxaparin for outpatients with COVID-19) randomized trial
Enoxaparin-Induced Liver Injury
Use of multiple laboratory tests including anti-factor Xa to optimally manage anticoagulation during ECMO
Anticoagulation
Webinar Anticoagulation
Quo vadis ECMO?
Anticoagulation in COVID-19: Effect of Enoxaparin, Heparin, and Apixaban on Mortality
Clinical controversies in anticoagulation monitoring and antithrombin supplementation for ECMO
Between a rock and a hard place: anticoagulation management for ECMO
Anticoagulation during ECMO: Will the Tight Rope be Tighter in 2018?
Comparison of anticoagulation strategies for veno-venous ECMO support in acute respiratory failure
Intravenous immunoglobulin fails to improve ARDS in patients undergoing ECMO therapy
Long-term course of ambulatory patients with COVID-19 initially treated with enoxaparin vs no anticoagulation: final analysis of the OVID (enoxaparin for outpatients with COVID-19) randomized trial
Enoxaparin-Induced Liver Injury
Use of multiple laboratory tests including anti-factor Xa to optimally manage anticoagulation during ECMO
Anticoagulation
Webinar Anticoagulation
Quo vadis ECMO?
Anticoagulation in COVID-19: Effect of Enoxaparin, Heparin, and Apixaban on Mortality
Clinical controversies in anticoagulation monitoring and antithrombin supplementation for ECMO
Between a rock and a hard place: anticoagulation management for ECMO
Anticoagulation during ECMO: Will the Tight Rope be Tighter in 2018?
Comparison of anticoagulation strategies for veno-venous ECMO support in acute respiratory failure
Intravenous immunoglobulin fails to improve ARDS in patients undergoing ECMO therapy
Long-term course of ambulatory patients with COVID-19 initially treated with enoxaparin vs no anticoagulation: final analysis of the OVID (enoxaparin for outpatients with COVID-19) randomized trial
Enoxaparin-Induced Liver Injury
Use of multiple laboratory tests including anti-factor Xa to optimally manage anticoagulation during ECMO
Anticoagulation
Webinar Anticoagulation